NVSNovartis PharmaceuticalsFinished
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Relapsing Multiple Sclerosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 562 (final count)
- Started
- Jul 14, 2020
- Main results expected
- Oct 9, 2024
- Fully finished
- Mar 11, 2025
- Results posted
- Nov 12, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Annualized Relapse Rate (ARR)
Measured over: Up to 96 weeks from baseline
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04353492 · record last updated 2026-04-09 · checked 2026-11-09 15:47 UTC